BLPH - Bellerophon Therapeutics, Inc.

0   0%

Share volume: 0
Last Updated:
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
N/A
P/E Ratio 
N/A
DAY RANGE
N/A - N/A
EPS 
N/A
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Peter Fernandes
Region: US
Website: bellerophon.com
Employees: 20
IPO year: 2015
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Bellerophon Therapeutics, Inc. focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform. InOpulse is in Phase 3 clinical trial for the. treatment of pulmonary hypertension associated with fibrotic interstitial lung disease.

Recent news